Multiple myeloma

August 17, 2021
Doctor talking with patient

Now Enrolling: EAA171/OPTIMUM for Myeloma

This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
February 25, 2021
Patient and doctor talking in office

Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma

The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients